What MapLight Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 6 | 12 |
| Sells | 8 | 145 |
| Total trades | 21 | 188 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 188 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Kreitzer Anatol | Chief Discovery Officer | Oct 15 | Sale for tax withholding · S | −12,248 | $7.84 | −$96K | 168,678 |
| Kroeger Christopher A. | Chief Executive Officer | Oct 15 | Sale for tax withholding · S | −73,691 | $8.08 | −$595K | 1,195,909 |
| Gillis Jonathan | CAO and Interim CFO | Oct 15 | Sale for tax withholding · S | −10,167 | $8.08 | −$82.1K | 142,315 |
| Hanson Kristopher | General Counsel | Oct 15 | Sale for tax withholding · S | −9,020 | $8.08 | −$72.9K | 128,024 |
| Foff Erin Pennock | Chief Medical Officer | Oct 15 | Sale for tax withholding · S | −15,355 | $8.08 | −$124K | 296,906 |
| Lillie James Woodruff | Chief Scientific Officer | Oct 15 | Sale for tax withholding · S | −11,513 | $8.08 | −$93K | 198,597 |
| Hanson Kristopher | General Counsel | Sep 16 | Open-market sale · S | −16,509 | $11.67 | −$193K | 137,044 |
| Lillie James Woodruff | Chief Scientific Officer | Aug 17 | Grant / award · A | +7,730 | — | — | 210,110 |
| Kreitzer Anatol | Chief Discovery Officer | Aug 17 | Grant / award · A | +6,020 | — | — | 180,926 |
| Foff Erin Pennock | Chief Medical Officer | Aug 17 | Grant / award · A | +13,360 | — | — | 312,261 |
| Gillis Jonathan | CAO and Interim CFO | Aug 17 | Grant / award · A | +2,222 | — | — | 152,482 |
| Gillis Jonathan | CAO and Interim CFO | Aug 17 | Grant / award · A | +6,020 | — | — | 150,260 |
| Kroeger Christopher A. | Chief Executive Officer | Aug 17 | Grant / award · A | +23,145 | — | — | 1,269,600 |
| Hanson Kristopher | General Counsel | Aug 17 | Grant / award · A | +7,730 | — | — | 153,553 |
| Catalyst4, Inc. | 10% owner | Aug 14 | Open-market buy · P | +4,400,000 | $11.38 | +$50.1M | 25,306,689 |
| Lillie James Woodruff | Chief Scientific Officer | Aug 03 | Open-market sale · S | −22,082 | $12.54 | −$277K | 202,380 |
| Catalyst4, Inc. | 10% owner | Jul 30 | Open-market buy · P | +1,000,000 | $13.00 | +$13M | 20,906,689 |
| Catalyst4, Inc. | 10% owner | Jul 29 | Open-market buy · P | +3,000 | $12.63 | +$37.9K | 19,906,689 |
| Cox Troy | Director | Jul 28 | Open-market buy · P | +15,620 | $9.52 | +$149K | 15,620 |
| Catalyst4, Inc. | 10% owner | Jul 28 | Open-market buy · P | +65,137 | $11.69 | +$761K | 19,903,689 |
Loading...
